Home
Resources
Product Analysis
Acknowledgements
About
Home
References
Organizations
Organizations
Actobio Therapeutics
Products 1 to 4 of 4
Modify Display Properties
Biotech components
Business models
Country of production
Country of distribution
Intended consumer
Date added
Date last modified
Known funding amount
Funding types
Industry
Market status
Organization
Organization type(s)
Product categories
Production process
Source
Trading symbol
Value chain stage
Sort: Title (A-Z)
Date added (oldest-newest)
Date added (newest-oldest)
Date modified (oldest-newest)
Date modified (newest-oldest)
Title (A-Z)
Title (Z-A)
Organization (A-Z)
Organization (Z-A)
ActoBiotics: AG013 (Oral Mucositis)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (5 years ago)
Date last modified:
2019/09/12 15:12 (5 years ago)
Known funding amount:
N/A
Funding types:
Government
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Personal Care (Topical)
+
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG017 (Celiac Disease)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (5 years ago)
Date last modified:
2019/09/16 16:28 (5 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Health
+
Medical
Market status:
Early Stage Concept
Organization type(s):
Private Company
Product categories:
Personal Care (Ingested)
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG018 (Rhinosinusitus)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (5 years ago)
Date last modified:
2019/09/12 15:12 (5 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Personal Care (Topical)
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG019 (Type 1 Diabetes)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (5 years ago)
Date last modified:
2019/09/12 15:12 (5 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Medical Treatment
+
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
Login
or
register
to add and edit products
Future
Bioengineered
Products
Home
Resources
Product Analysis
Acknowledgements
About
